These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 38581716)

  • 1. Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review.
    Li YQ; Chen XM; Si GF; Yuan XM
    Biomol Biomed; 2024 Apr; 24(4):764-774. PubMed ID: 38581716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors: breakthroughs in cancer treatment.
    Kong X; Zhang J; Chen S; Wang X; Xi Q; Shen H; Zhang R
    Cancer Biol Med; 2024 May; 21(6):451-72. PubMed ID: 38801082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
    Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
    J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
    El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody.
    Dai T; Sun H; Liban T; Vicente-Suarez I; Zhang B; Song Y; Jiang Z; Yu J; Sheng J; Lv B
    Sci Rep; 2024 May; 14(1):10661. PubMed ID: 38724599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade.
    Lecocq Q; Awad RM; De Vlaeminck Y; de Mey W; Ertveldt T; Goyvaerts C; Raes G; Thielemans K; Keyaerts M; Devoogdt N; Breckpot K
    J Nucl Med; 2021 Nov; 62(11):1638-1644. PubMed ID: 33712537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte-activation gene-3, an important immune checkpoint in cancer.
    He Y; Rivard CJ; Rozeboom L; Yu H; Ellison K; Kowalewski A; Zhou C; Hirsch FR
    Cancer Sci; 2016 Sep; 107(9):1193-7. PubMed ID: 27297395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma.
    Zelba H; Bedke J; Hennenlotter J; Mostböck S; Zettl M; Zichner T; Chandran A; Stenzl A; Rammensee HG; Gouttefangeas C
    Cancer Immunol Res; 2019 Nov; 7(11):1891-1899. PubMed ID: 31484656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-LAG-3 boosts CD8 T cell effector function.
    Kureshi CT; Dougan M; Dougan SK
    Cell; 2024 Aug; 187(16):4144-4146. PubMed ID: 39121844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LAGging behind no more: PD-1 has a new immunotherapy partner.
    Gunderson AJ
    Immunity; 2024 Oct; 57(10):2266-2268. PubMed ID: 39383843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
    Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
    Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
    Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy.
    Qi Y; Chen L; Liu Q; Kong X; Fang Y; Wang J
    Front Immunol; 2020; 11():563258. PubMed ID: 33488573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
    Kreidieh FY; Tawbi HA
    Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes.
    Lee WJ; Lee YJ; Choi ME; Yun KA; Won CH; Lee MW; Choi JH; Chang SE
    J Am Acad Dermatol; 2019 Jul; 81(1):219-227. PubMed ID: 30880064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions.
    Esen F; Deniz G; Aktas EC
    Immunol Lett; 2021 Dec; 240():15-23. PubMed ID: 34599946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets.
    Chocarro L; Blanco E; Fernandez-Rubio L; Garnica M; Zuazo M; Garcia MJ; Bocanegra A; Echaide M; Johnston C; Edwards CJ; Legg J; Pierce AJ; Arasanz H; Fernandez-Hinojal G; Vera R; Ausin K; Santamaria E; Fernandez-Irigoyen J; Kochan G; Escors D
    EMBO Mol Med; 2024 Aug; 16(8):1791-1816. PubMed ID: 39030301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.
    Burugu S; Gao D; Leung S; Chia SK; Nielsen TO
    Ann Oncol; 2017 Dec; 28(12):2977-2984. PubMed ID: 29045526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.